Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tissue company looks to cardiovascular repair implant

This article was originally published in Clinica

Executive Summary

US start-up company Reprogenesis has announced plans to begin Phase I trials of a bioactive vascular repair implant within 12 months. The RP-VAD implant combines allogenic endothelial cells with a polymer matrix and is designed to restore the function of endothelial cells lining vessels which have been damaged during surgery or vascular access procedures.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079891

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel